Non-invasive bladder urothelial carcinoma

Researchers are testing whether drug testing in patient-derived organoids can guide chemotherapy for low-grade non-muscle invasive bladder cancer. Adults with primary or recurrent low-grade bladder cancer receive one of four chemo drugs, epirubicin, mitomycin C, gemcitabine, or d…

This phase 2 trial is testing an experimental drug called RAG-01, either alone or combined with chemotherapy, in people with a type of bladder cancer that hasn't spread into the muscle layer. The study aims to see if the drug can improve how long patients go without their cancer …

This phase 2 trial tests whether combining the immunotherapy drug toripalimab with the chemotherapy drug gemcitabine, given directly into the bladder, can reduce the chance of high-risk non-muscle-invasive bladder cancer returning after surgery. Adults aged 18 to 85 who have had …

This study tests whether adding chemotherapy drugs (gemcitabine and mitomycin C) directly into the bladder alongside an immune-boosting drug (toripalimab) works better than toripalimab alone for people with a high-risk bladder cancer that did not respond to standard BCG therapy. …

This Phase 3 trial tests NDV-01, a sustained-release combination of two chemotherapy drugs (gemcitabine and docetaxel), given directly into the bladder. It aims to prevent cancer from coming back in people with non-muscle invasive bladder cancer, including those who have not resp…

This trial is testing a device that delivers heated chemotherapy directly into the bladder for people with non-muscle invasive bladder cancer. The goal is to see if the system is safe and works as intended. Participants will receive the treatment and be monitored for side effects…

This trial asks whether some people with intermediate-risk bladder cancer can safely skip chemotherapy after having their tumor removed. Doctors will use a urine test before surgery to find patients whose tumors are unlikely to shed detectable signals. These patients will then be…

This trial tests whether a newer surgical method called en bloc resection, which removes bladder tumors in one piece, works better than the standard piecemeal approach for people with intermediate- or high-risk non-muscle-invasive bladder cancer. All participants also receive a y…

This trial tests whether an artificial intelligence system can help surgeons better see and remove bladder tumors during a standard procedure called TURBT. The AI analyzes the live video from the surgical camera and highlights suspicious areas and recommended cutting edges on the…

This early-phase trial is testing a new biologic drug, UGN-501, for people whose non-muscle invasive bladder cancer has returned after previous treatment. The drug is given directly into the bladder through a catheter once a week for six weeks, with possible quarterly maintenance…

This early-stage trial tests a new drug called ATO-101 for a type of bladder cancer that hasn't responded to standard treatments. The drug delivers a short-range radioactive particle directly into the bladder to kill cancer cells while sparing healthy tissue. About 24 patients wi…

This study looks at people with a very high-risk type of bladder cancer that cannot be fully removed with standard surgery. After initial treatment with immunotherapy and surgery, some patients become tumor-free. The trial then randomly assigns them to either continue immunothera…

This study tests a treatment called HIVEC, which delivers heated chemotherapy directly into the bladder. It is for people with a type of bladder cancer that has not responded to standard therapy and who cannot have their bladder removed. The goal is to see if this approach is saf…

This early-phase trial tests a new biologic drug called SPGL008, given alone or with the standard therapy BCG, in 120 people with high-risk non-muscle-invasive bladder cancer who are not candidates for bladder removal. The main goals are to find a safe dose and see if the drug ca…

This study looks at whether veterans with early-stage high-grade bladder cancer can have fewer follow-up exams (cystoscopies) without harming their health. About 2,500 participants will be randomly assigned to either a low-intensity or high-intensity surveillance schedule. The go…

This phase 2 trial tests whether a drug called N-803, combined with either BCG or gemcitabine, can treat intermediate-risk bladder cancer without needing surgery. About 20 adults with low-grade papillary tumors will receive the drugs directly into the bladder. The main goal is to…

This study tests whether injecting the chemotherapy drug gemcitabine directly into the bladder wall can prevent cancer from coming back in people with intermediate- or high-risk non-muscle-invasive bladder cancer. About 320 participants will receive either the new injection or th…

This trial tests whether a fluorescent dye called TTP-ICG, which targets a protein found on bladder cancer cells, can help surgeons spot tumors during surgery. People with suspected or confirmed non-muscle invasive bladder cancer will have the dye placed into their bladder before…

Researchers are testing whether heated saline can be safely given during surgery to remove early bladder tumors. The study enrolls adults with small papillary tumors that have not grown into the bladder muscle. Participants receive either heated saline or room-temperature saline …

This trial tests a personalized home-based supportive care program for people with non-muscle-invasive bladder cancer who receive intravesical perfusion therapy after surgery. The program provides physical symptom relief, psychological support, and education to help patients mana…

This study looks at the well-being and medical care of people in Korea who had their bladder removed (radical cystectomy) for bladder cancer. Using nationwide insurance records, researchers will track complications, hospital stays, readmissions, and survival up to three years aft…

This study examines two microscopic details in bladder cancer tumors—how deep early cancer cells have invaded and whether small clusters of cells are present at the tumor's edge. Researchers will look at tissue samples from 100 patients to see if these features can predict if the…

This observational study will follow 150 adults with early-stage bladder cancer to see if factors like muscle loss, fat distribution, and nutrition affect the chance of cancer coming back or getting worse. Participants will have standard treatments and extra assessments including…